Are SLS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SLS leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / SLS / insiders

XERS (64) SRPT (27) BRVE (46) TRVI (30) ⌘ Pro Terminal →

SELLAS Life Sciences Group Inc. (SLS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$9.68 -4.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.58

SELLAS Life Sciences Group Inc. (SLS) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.95B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SLS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, SELLAS Life Sciences Group Inc. (NASDAQ: SLS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $9.68 (-4.68% 1D, market cap $1.95B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SLS ranks #498 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SLS compare to XERS and SRPT in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLS carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -21.8%. By comparison, XERS (Xeris Biopharma Holdings Inc.) holds a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.95B) and SRPT (Sarepta Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $1.97B). Among the 5-stock peer group, SLS leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SLS?

▼

Per SLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001390478), SELLAS Life Sciences Group Inc. generated $79.2M in revenue (-10.3% YoY), -$26.9M in net income, and -$28.4M in free cash flow against $78.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.58 (-1.03%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SLS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY SLS SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 57% of 52W Range • RSI-14 at 39.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$12.41-3.5% Next Q

Q2 (-2Q)

Grade D$11.98+1.6% Next Q

Q3 (-1Q)

Grade D$12.17-20.5% Next Q

Current

Grade D-$9.68-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SLS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SLS currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.96) and Max Pain ($10.16) forces dealer call-delta covering toward $16.67.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SLS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SLS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SLS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SLS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SLS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SLS)

✓Walkthrough of SLS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SLS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +92.83%🛡️ HOLDING TREND SUPPORT

2026-11-03O $10.15H $10.15L $9.68C $9.68VOL 6.26M

RES: $15.38SUP: $9.30SMA50: $11.96SMA200: $8.63

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SLS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SLS Butterfly Map → + Track SLS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -10.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SLS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SLS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SLS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SLS)

Health Care Rank #498 of 1015 ⚔️ XERS vs SLS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SLS vs. XERS, SRPT, BRVE, TRVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, SELLAS Life Sciences Group Inc. (SLS) ranks #498 by composite RQD confidence (38/100, grade D-) and #258 by equity capitalization ($1.95B). Within this direct 5-issuer industry benchmark cohort, SLS leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with SLS at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SLS ACTIVE SELLAS Life Sciences Group Inc.	D-	38/100	—	—	-21.8%	-4.68%	$1.95B	Benchmark Subject
XERS Xeris Biopharma Holdings Inc.	C	64/100	—	—	16.0%	-0.37%	$1.95B	/xers-vs-sls →
SRPT Sarepta Therapeutics Inc.	E	27/100	—	96.0%	-35.0%	-3.17%	$1.97B	/srpt-vs-sls →
BRVE Braveheart Bio Inc.	D	46/100	—	—	—	+1.51%	$1.94B	/brve-vs-sls →
TRVI Trevi Therapeutics Inc.	E	30/100	—	—	-23.7%	-1.81%	$1.93B	/trvi-vs-sls →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001390478 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SELLAS Life Sciences Group Inc. (SLS) reported GAAP revenue of $79.2M (-10.3% vs. FY2024 revenue of $88.2M , and -25.3% cumulative change since FY2023) , GAAP net income of -$26.9M, operating cash flow of -$28.4M, and free cash flow of -$28.4M (+19.8% YoY). On the balance sheet, SLS closed FY2025 with $78.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$79.2M	-$26.9M	-$28.4M	-$28.4M	$78.3M	—
FY2024 (FY)	2024-12-31	$88.2M	-$30.9M	-$35.4M	-$35.4M	$19.4M	—
FY2023 (FY)	2023-12-31	$106.0M	-$37.3M	-$31.4M	-$31.4M	—	—

3. SLS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SLS compare to XERS and SRPT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SLS?

Where is SLS trading relative to its 50-day, 200-day, and 52-week technical levels?

SLS last traded at $9.68 (-4.68% on volume of 6,262,245 shares), positioning the stock -19.06% below its 50-day simple moving average ($11.96) and +12.17% above its 200-day simple moving average ($8.63). Across its 52-week range of $1.39 to $15.88, SLS sits at the 57.2% percentile with a 14-day RSI of 39.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.47 to $10.89).

Direct Sub-Reports: SLS RQD Cockpit SLS 12M Forecast SLS Earnings & Move SLS Dividends & DRIP SLS Insiders & 13F SLS Whale Options SLS Profit Sankey SLS News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ SEC XBRL & RQD VERIFIED

SLS — SELLAS Life Sciences Group Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

SELLAS Life Sciences Group Inc. (SLS) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $9.68 (-4.68% 1D, market capitalization $1.95B).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -21.8%, gross margin of —, operating margin of —, and free cash flow yield of -1.38%.
Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

SELLAS Life Sciences Group Inc. Is a NASDAQ-listed issuer in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry,. Revenue is reported as — across the financial periods provided. — for product details, customers, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), SELLAS Life Sciences Group Inc. (SLS) reported $79.2M in annual revenue (up from $88.2M in FY2024, -10.3% YoY) and -$26.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($106.0M revenue, -$37.3M net income) through FY2025, SLS scaled operating cash flow to -$28.4M and free cash flow to -$28.4M, backed by $78.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -1.38% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $1.39 – $15.88 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream links and no proprietary signals recorded (supply_chain: NONE). Sector correlations beyond the Health Care sector classification are — Second-order bottlenecks cannot be mapped from the source data; a careful investor should note that the absence of recorded links means the source data cannot identify supplier or customer dependencies.

Key Question #1: Can SLS sustain or expand its — operating margin and -21.8% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $79.2M and free cash flow of -$28.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is SLS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SLS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SELLAS Life Sciences Group Inc. (SLS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SLS Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 1d ago

SELLAS Life Sciences Group (SLS) Dropped, So What Is Behind The Latest Attention?

Yahoo Finance report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Sellas Life Sciences: The Longer The Wait, The More Likely A REGAL Failure (NASDAQ:SLS)

Seeking Alpha report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

SELLAS Life Sciences Stock Stumbles: What's Going On?

Benzinga report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Barchart.com • 1d ago

SLS Price History for Sellas Life Sciences Group Stock

Barchart.com report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stocktwits • 1d ago

SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years

Stocktwits report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

SELLAS Life Sciences Group (Nasdaq:SLS) - Stock Analysis

Simply Wall St report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Moomoo • 1d ago

We're Not Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn

Moomoo report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Singapore • 1d ago

SELLAS Life Sciences Group, Inc. (SLS) stock price, news, quote and history

Yahoo Finance Singapore report covering SELLAS Life Sciences Group Inc. (SLS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SLS Bull vs. Bear Conversation Board — What's Your Call at $9.68?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SLS 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $11.13 (+15.0%)

📌 Pinned Debate

Cash rose to $71.8M in FY 2025 from $13.9M in FY 2024, a potential funding cushion against reported operating losses of -$28.3M.

Cash rose to $71.8M in FY 2025 from $13.9M in FY 2024, a potential funding cushion against reported operating losses of -$28.3M.. When you look under the hood at SLS, Fundamental Cash Engine is 7/20 with 0.0% gross margins and -21.8% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (8/20) has been quietly accumulating below $15.88. My 12M target is $11.13.

EarningsSniper 🐂 BULL

Both sides have a point here — SLS's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $7.45 (-23.0%)

Spot @ $9.68

Negative ROIC of -21.8% and FCF yield of -1.38% against a $2.05B market cap leave the valuation dependent on future cash generation not

Negative ROIC of -21.8% and FCF yield of -1.38% against a $2.05B market cap leave the valuation dependent on future cash generation not yet shown in the data.. Look at the math on SLS: paying current EV/EBITDA multiples for -21.8% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $8.52 before getting long.